Anzeige
Mehr »
Login
Sonntag, 12.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Die 1 Billionen Dollar Mine: Power Nickels Weg zur globalen Dominanz!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
249 Leser
Artikel bewerten:
(1)

Menarini Industrie Farmaceutiche Riunite: THE DOORS OF EUROPE OPEN WIDE FOR THE VOLPI ROSSE MENARINI

Finanznachrichten News

The Florentine team qualifies for Eurocup 3 by winning the qualification tournament in France.

The first time in history for a Tuscan team.

FLORENCE, Italy, May 2, 2023 /PRNewswire/ -- The Menarini Volpi Rosse team has now crossed the border and is on their way to Europe. The Florentine team will be the first wheelchair basketball team to represent Tuscany on an international level in the Eurocup 3.

Volpi Rosse Menarini (PRNewsfoto/Menarini Industrie Farmaceutiche Riunite)

An absolute debut in Europe in an official, international tournament of the Iwbf, the European Wheelchair Basketball Federation. The extraordinary result this young, Florence-based team brought home was part of the qualification tournament that took place over the weekend in Chalon-Sur-Saône, in Burgundy (France). Being able to take part in this tournament was also thanks to the team's constant and exponential growth that allowed the team - just in its second year in Serie A - to be high enough in the ranking to take part in the European qualification matches.

Moreover, the Menarini Volpi Rosse team was left undefeated after the games played in France, first they defeated their opponents Elan Chalon (France), then the Belgians Roller Poulls and, finally, the Israeli team of Maid El Karam. In addition to which the team, just a few days later, went on to beat the Belgian team Roller Poulls in the final.

"This is an incredible result and a source of great satisfaction for the team - declared the President of the Volpi Rosse Menarini, Ivano Nuti - We faced our European debut with a sense of humbleness and openness that our young team also displayed on court. This approach allowed us to achieve a historical result, not only for the team, but for the entire Tuscan wheelchair basketball movement".

The French tournament, where the Volpi Rosse team not only bore the name of Menarini but also represented the 'Pegasus' for the Tuscan Region and the 'Giglio' (lily), ensign of the city of Florence, came at the end of a season of great results for the team. "Out of a total of seventeen matches between the league and Europe - concluded Nuti - we won twelve. In the league we finished fifth and came in sixth in terms of goal difference after the play-off against Padua. Whilst we were beaten at home, we won the away match which made us the only team to defeat the Venetian team at home".

"The result acheived by the Volpi Rosse is a source of great pride for Menarini - added Lucia and Alberto Giovanni Aleotti, shareholders and members of the Menarini Board of Directors - The spirit and commitment dedicated by the team on court every day are the foundation of such important results and represent, in the best possible way, the values that have always characterised our Company. Congratulations to the young players - concluded Lucia and Alberto Giovanni Aleotti - they are a true example to follow, not only in sport but in everyday life".

The Menarini Pharmaceutical Group, with headquarters in Florence, is present in 140 countries worldwide to date, with €4,154 million in turnover and more than 17,000 employees. With 9 centres for Research & Development, Menarini's products are present in the most important treatment areas, including those of cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesic products. Pharmaceutical production is carried out in the Group's 18 manufacturing plants, located in Italy and abroad, which produce over 577 million packets of product a year and distribute them to five continents. Menarini's pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients throughout the world. For further information please visit www.menarini.com

Photo - https://mma.prnewswire.com/media/2067783/Volpi_Rosse_Menarini_1.jpg
Photo - https://mma.prnewswire.com/media/2067784/Volpi_Rosse_Menarini_2.jpg
Photo - https://mma.prnewswire.com/media/2067785/Volpi_Rosse_Menarini_3.jpg
Logo - https://mma.prnewswire.com/media/1958938/4015397/MENARINI_GROUP_Logo.jpg

Volpi Rosse Menarini (PRNewsfoto/Menarini Industrie Farmaceutiche Riunite)

Volpi Rosse Menarini (PRNewsfoto/Menarini Industrie Farmaceutiche Riunite)

(PRNewsfoto/Menarini Industrie Farmaceutiche Riunite)

Cision View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/the-doors-of-europe-open-wide-for-the-volpi-rosse-menarini-301813076.html

© 2023 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.